Atom­wise inks Chi­na deal as list of AI col­lab­o­ra­tions length­ens

The long list of ma­jor AI bio­phar­ma col­lab­o­ra­tions has got­ten longer as one of the first ar­ti­fi­cial in­tel­li­gence star­tups has inked its first deal in Chi­na.

San Fran­cis­co-based start­up Atom­wise has signed an agree­ment to de­vel­op tar­get­ed drugs with Han­soh Phar­ma­ceu­ti­cals, a deal that could ul­ti­mate­ly be worth up to $1.5 bil­lion. Han­soh is flush with cash af­ter a $1 bil­lion IPO on the Hong Kong ex­change in June.

The promise of ma­chine learn­ing to speed up pre­clin­i­cal work and save de­vel­op­ers mil­lions of dol­lars has led to a string of new col­lab­o­ra­tions be­tween a hand­ful of soft­ware star­tups and some of the biggest drug de­vel­op­ers and re­search in­sti­tu­tions in­clud­ing Mer­ck, As­traZeneca, J&J, Bris­tol-My­ers Squibb, Pfiz­er and Duke Uni­ver­si­ty School of Med­i­cine. They’ve agreed to work on re­search rang­ing from on­col­o­gy to chron­ic dis­ease.

Part of the swarm like­ly comes from the hype that pe­ri­od­i­cal­ly sur­rounds a new tech­nol­o­gy — and few words are buzzi­er right now in both tech and pop­u­lar cul­ture than “ar­ti­fi­cial in­tell­gien­ce” and “ma­chine learn­ing” — and that has con­cerned some key fig­ures in phar­ma­ceu­ti­cal de­vel­op­ment. But al­though it’s too ear­ly for the AI plat­forms to have brought a drug to mar­ket, ear­ly stud­ies have in­di­cat­ed there could be some­thing be­neath the buzz. That in­cludes last week’s land­mark study from In­sil­i­co in Na­ture Biotech­nol­o­gy, in which over 21 days the com­pa­ny found six mol­e­cules that could be po­ten­tial treat­ments for fi­bro­sis.

At its most ba­sic, ar­ti­fi­cial in­tel­li­gence works like this: You feed an AI sys­tem a vast num­ber of, say, im­ages of a cow and im­ages not of a cow, and you tell it which is which. With each im­age of a cow and not-cow, the AI de­vel­ops a more and more re­fined set of cri­te­ria for what con­sti­tutes a cow (even if that cri­te­ria is far dif­fer­ent from what a hu­man might give). Pret­ty soon it can very ac­cu­rate­ly rec­og­nize whether a new pic­ture has a cow or not. You can al­so do this with, say, an im­age of your mom. It’s how your iPhone’s fa­cial recog­ni­tion works.

And you can do this with a mol­e­cule.

Atom­wise works by what’s called “vir­tu­al screen­ing,” mean­ing it us­es its AI sys­tem to rapid­ly search data­bas­es for mol­e­cules that re­sem­ble what its part­ners are look­ing for. Its June part­ner­ship with Ukraine-based Et­a­mine, the world’s largest chem­i­cal sup­pli­er, gives it ac­cess to a data­base of bil­lions of com­pounds to scan. Atom­wise can scan 10-20 mil­lion per day, up from con­ven­tion­al com­put­er meth­ods that cap out at about 100,000. This lat­est deal with Han­soh will see the com­pa­ny de­sign and dis­cov­er drugs for 11 undis­closed tar­get pro­teins.

How­ev­er, the In­sil­i­co study that grabbed head­lines was for a slight­ly dif­fer­ent form of AI.

This new­er AI, on­ly put forth in 2014, goes fur­ther. Rather than rec­og­niz­ing a face, it can imag­ine a face (or, say, art). The idea In­sil­i­co is bet­ting on and get­ting close to prov­ing is that if it can imag­ine a face, it can imag­ine a drug. Ac­cord­ing­ly, these are called “gen­er­a­tive” net­works, as op­posed to the “con­vo­lu­tion­al” ones Atom­wise us­es.

We’ll use cows again for the mod­el. These new AIs ac­tu­al­ly con­sist of two sys­tems. Loaded with da­ta, the “gen­er­a­tive” one at­tempts to come up with an im­age of a cow. Then a sec­ond one, which is called the “dis­crim­i­na­tor” and works likes the tech de­scribed above, tells the gen­er­a­tive one if it got a cow or not. The gen­er­a­tor learns from the dis­crim­i­na­tor, which learns from the vast store of up­loaded in­for­ma­tion. You have a learn­ing feed­back loop that should even­tu­al­ly gets you a brand new pret­ty pic­ture of a cow.

In the In­sil­i­co study, they were search­ing for a new ty­ro­sine ki­nase in­hibitor for dis­coidin do­main re­cep­tor 1 (DDR1). The sys­tem was taught all DDRI lit­er­a­ture, a larg­er set of ki­nase in­hibitors, data­bas­es of med­i­c­i­nal­ly ac­tive struc­tures and a data­base of struc­tures that have al­ready been patent­ed. The re­sult? 30,000 can­di­date struc­tures, which the com­pa­ny then whit­tled down to 40. They pro­duced 6 of them in the lab, test­ed 2 of them on cells and one on mice.

Promi­nent sci­ence writer and not­ed skep­tic of biotech AI hype Derek Lowe damp­ened the ex­u­ber­ant head­lines, not­ing the DDRI is al­ready well re­searched (cre­at­ing an ide­al sam­ple size to train the neur­al net­works), the dis­cov­er­ies weren’t drugs but pos­si­ble drug tar­gets, and gen­er­al­iz­ing these tech­niques to oth­er drug ar­eas will take years and lots of cash. This ac­cords with a con­sen­sus view of the tri­al as a proof-of-con­cept. Still, he found it one of the most in­ter­est­ing pa­pers he had read on vir­tu­al screen­ing.

“The good news, though, is that there is no rea­son that vir­tu­al screen­ing can’t do great things, even­tu­al­ly,” he wrote in his blog, In the Pipeline. “We just have to get a lot bet­ter at it than we are now, and that’s as true as it was when I first heard about it in the mid-1980s.”

De­vel­op­ment of the Next Gen­er­a­tion NKG2D CAR T-cell Man­u­fac­tur­ing Process

Celyad’s view on developing and delivering a CAR T-cell therapy with multi-tumor specificity combined with cell manufacturing success
Overview
Transitioning potential therapeutic assets from academia into the commercial environment is an exercise that is largely underappreciated by stakeholders, except for drug developers themselves. The promise of preclinical or early clinical results drives enthusiasm, but the pragmatic delivery of a therapy outside of small, local testing is most often a major challenge for drug developers especially, including among other things, the manufacturing challenges that surround the production of just-in-time and personalized autologous cell therapy products.

Paul Hudson, Getty Images

UP­DAT­ED: Sanofi CEO Hud­son lays out new R&D fo­cus — chop­ping di­a­betes, car­dio and slash­ing $2B-plus costs in sur­gi­cal dis­sec­tion

Earlier on Monday, new Sanofi CEO Paul Hudson baited the hook on his upcoming strategy presentation Tuesday with a tell-tale deal to buy Synthorx for $2.5 billion. That fits squarely with hints that he’s pointing the company to a bigger future in oncology, which also squares with a major industry tilt.

In a big reveal later in the day, though, Hudson offered a slate of stunners on his plans to surgically dissect and reassemble the portfoloio, saying that the company is dropping cardio and diabetes research — which covers two of its biggest franchise arenas. Sanofi missed the boat on developing new diabetes drugs, and now it’s pulling out entirely. As part of the pullback, it’s dropping efpeglenatide, their once-weekly GLP-1 injection for diabetes.

“To be out of cardiovascular and diabetes is not easy for a company like ours with an incredibly proud history,” Hudson said on a call with reporters, according to the Wall Street Journal. “As tough a choice as that is, we’re making that choice.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,300+ biopharma pros reading Endpoints daily — and it's free.

Roger Perlmutter, Merck

#ASH19: Here’s why Mer­ck is pay­ing $2.7B to­day to grab Ar­Qule and its next-gen BTK drug, lin­ing up Eli Lil­ly ri­val­ry

Just a few months after making a splash at the European Hematology Association scientific confab with an early snapshot of positive data for their BTK inhibitor ARQ 531, ArQule has won a $2.7 billion buyout deal from Merck.

Merck is scooping up a next-gen BTK drug — which is making a splash at ASH today — from ArQule in an M&A pact set at $20 a share $ARQL. That’s more than twice Friday’s $9.66 close. And Merck R&D chief Roger Perlmutter heralded a deal that nets “multiple clinical-stage oral kinase inhibitors.”

This is the second biotech buyout pact today, marking a brisk tempo of M&A deals in the lead-up to the big JP Morgan gathering in mid-January. It’s no surprise the acquisitions are both for cancer drugs, where Sanofi will try to make its mark while Merck beefs up a stellar oncology franchise. And bolt-ons are all the rage at the major pharma players, which you could also see in Novartis’ recent $9.7 billion MedCo buyout.

ArQule — which comes out on top after their original lead drug foundered in Phase III — highlighted early data on ‘531 at EHA from a group of 6 chronic lymphocytic leukemia patients who got the 65 mg dose. Four of them experienced a partial response — a big advance for a company that failed with earlier attempts.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,300+ biopharma pros reading Endpoints daily — and it's free.

Paul Hudson, Sanofi

Paul Hud­son promis­es a bright new fu­ture at Sanofi, kick­ing loose me-too drugs and fo­cus­ing on land­mark ad­vances. But can he de­liv­er?

Paul Hudson was on a mission Tuesday morning as he stood up to address Sanofi’s new R&D and business strategy.

Still fresh into the job, the new CEO set out to convince his audience — including the legions of nervous staffers inevitably devoting much of their day to listening in — that the pharma giant is shedding the layers of bureaucracy that had held them back from making progress in the past, dropping the duds in the pipeline and reprioritizing a more narrow set of experimental drugs that were promised as first-in-class or best-in-class.  The company, he added, is now positioned to “go after other opportunities” that could offer a transformational approach to treating its core diseases.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,300+ biopharma pros reading Endpoints daily — and it's free.

Am­gen puts its foot down in shiny new South San Fran­cis­co hub as it re­or­ga­nizes R&D ops

Amgen has signed up to be AbbVie’s neighbor in South San Francisco as it moves into a nine-story R&D facility in the booming biotech hub.

The arrangement gives Amgen 240,000 square feet of space on the Gateway of Pacific Campus, just a few minutes drive from its current digs at Oyster Point. The new hub will open in 2022 and house the big biotech’s Bay Area employees working on cardiometabolic, inflammation and oncology research.

Ab­b­Vie, Scripps ex­pand part­ner­ship, for­ti­fy fo­cus on can­cer drugs

Scripps and AbbVie go way back. Research conducted in the lab of Scripps scientist Richard Lerner led to the discovery of Humira. The antibody, approved by the FDA in 2002 and sold by AbbVie, went on to become the world’s bestselling treatment. In 2018, the drugmaker and the non-profit organization signed a pact focused on developing cancer treatments — and now, the scope of that partnership has broadened to encompass a range of diseases, including immunological and neurological conditions.

South Ko­rea jails 3 Sam­sung ex­ecs for de­stroy­ing ev­i­dence in Bi­o­Log­ics probe

Three Samsung executives in Korea are going to jail.

The convictions came in what prosecutors had billed as “biggest crime of evidence destruction in the history of South Korea”: a case of alleged corporate intrigue that was thrown open when investigators found what was hidden beneath the floor of a Samsung BioLogics plant. Eight employees in total were found guilty of evidence tampering and the three executives were each sentenced to up to two years in prison.

Nick Plugis, Avak Kahvejian, Cristina Rondinone, Milind Kamkolkar and Chad Nusbaum. (Cellarity)

Cel­lar­i­ty, Flag­ship's $50M bet on net­work bi­ol­o­gy, mar­ries ma­chine learn­ing and sin­gle-cell tech for drug dis­cov­ery

Cellarity started with a simple — but far from easy — idea that Avak Kahvejian and his team were floating around at Flagship Pioneering: to digitally encode a cell.

As he and his senior associate Nick Plugis dug deeper into the concept, they found that most of the models others have developed take a bottom-up approach, where they assemble the molecules inside cells and the connections between them from scratch. What if they opt for a top-down approach, aided by single-cell transcriptomics and machine learning, to gauge the behavior of the entire cellular network?

Sanofi’s big week in­cludes a promis­ing PhI­II for an or­phan dis­ease drug, with plans for a pitch to the FDA

The biopharma R&D food chain is paying off with a plan at Sanofi to pitch regulators on a new drug for an orphan disease called cold agglutinin disease.

The pharma giant ushered out a statement Tuesday morning — after it spelled out plans to radically restructure the company, abandoning cardio and diabetes research altogether — saying that their C1s inhibitor sutimlimab had cleared the pivotal study.